Last updated: 2026-09-09 12:53:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Iovance Biotherapeutics, Inc. (IOVA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.74, with a market capitalization of $3.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.76 to $9.36. This page covers its latest market performance, valuation, price trends and company information.
$3.98B | |
$8.72 | |
$54.21 | |
$1.64 | |
$8.70 | |
88.00K | |
16.15M | |
-- | |
$9.36 | |
$1.76 | |
-- | |
-- |
Iovance Biotherapeutics, Inc. (IOVA) is trading at $8.74 in pre-market trading as of 2026-09-09 12:51:00, up 0.41% ($0.04) from the previous close of $8.70
Pre-market trading shows how investors are pricing IOVA before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Iovance Biotherapeutics, Inc. (IOVA) moved from $8.01 to $8.74, representing a gain of 9.06% ($0.73).
The stock traded between $7.66 and $8.91 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 10.18 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 91.8%
IOVA is currently trading at $8.74, placing it 91.8% of the way from its 52-week low of $1.76 to its 52-week high of $9.36. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 975 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Iovance Biotherapeutics, Inc. (IOVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.